-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nuocheng Jianhua announced today that the company's self-developed highly selective pan-FGFR (fibroblast growth factor receptor) inhibitor gunagratinib (ICP-192) has been granted Orphan Drug designation by the U.
S.
Food and Drug Administration (FDA).
Designation, ODD), used to treat cholangiocarcinoma
.
ICP-192 is a class 1 innovative drug with global independent intellectual property rights under Nuocheng Jianhua.
It is a small molecule pan-FGFR inhibitor that can be used to treat a variety of solid tumors and is highly selective.
It is currently conducting multiple clinical trials in China and the United States.
Research
.
The latest clinical data of gunagratinib announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting shows that as of February 2021, a total of 30 patients have received gunagratinib treatment
.
The safety and tolerance are good, and the maximum tolerated dose (MTD) has not been reached
Note: The original text has been deleted